Katherine Stueland sold $3.2M of WGS
Chief Executive Officer at GeneDx Holdings Corp.. 45,415 shares at an average of $70.41, traded Nov 15, 2024, filed Nov 19, 2024.
Score components
- +25RoleCEO
- +25Trade size$3.2M at market
- +10Share of holdings soldSold 43% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.0%, 3m +58.7%, 6m +1.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027270, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -5,497 | $68.65 | $377k | 99,929 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -4,800 | $69.67 | $334k | 95,129 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -7,240 | $70.72 | $512k | 87,889 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,958 | $71.49 | $140k | 85,931 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -2,043 | $72.95 | $149k | 83,888 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,510 | $73.71 | $111k | 82,378 | Nov 19, 2024 |
| Nov 15, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -60 | $74.34 | $4,460 | 82,318 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -800 | $66.60 | $53k | 81,518 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -459 | $67.94 | $31k | 81,059 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,151 | $68.98 | $217k | 77,908 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -6,186 | $70.15 | $434k | 71,722 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -8,580 | $70.91 | $608k | 63,142 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,131 | $71.83 | $225k | 60,011 | Nov 19, 2024 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 56Moderate | WGSbuy GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $11M 200,000 shares | +6% | |
| 59Moderate | GeneDx Holdings Corp. | Casdin Capital, LLC director, owner | $21M 500,000 shares | +17% | |
| 64Notable | GeneDx Holdings Corp. | Keith A. Meister director, owner | $14M 351,273 shares | +8% | |
| 67Notable | GeneDx Holdings Corp. | Keith A. Meister director, owner | $47M 1,205,147 shares | +37% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.